HOME
市場調査レポート
がんプロファイリングの世界市場：技術別、がんタイプ別2024年予測
Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
- 出版元：MarketsandMarkets
出版元について - 発行年：2019年6月
- 定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文224ページになります。
- 商品コード：MAM1592
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
がんプロファイリングの世界市場規模は2019年の推計75億ドルから、今後2024年には124億ドル市場へと拡大が見込まれます。当レポートでは、2024年に至るがんプロファイリングの世界市場予測(市場規模US$)、技術別市場（免疫測定、次世代シーケング、ポリメラーゼ連鎖反応、in situハイブリダイゼーション、マイクロアレイ、マススペクトロメトリー、その他）、がんタイプ別市場（乳がん、肺がん、結腸直陽がん、前立腺がん、メラノーマ、その他）、バイオマーカータイプ別市場（遺伝子、タンパク質、その他）、用途別市場（研究各種、臨床各種）、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業12社プロフィール動向などの情報も交えて、がんプロファイリング市場の現在と今後展開を予測分析していきます。
【レポート構成概要】 
◆がんプロファイリングの世界市場予測2017-2024年
・市場規模(US$)
◆技術別、市場-2024年
・免疫測定
・次世代シーケンシング(NGS)
・ポリメラーゼ連鎖反応(PCR)
・in situハイブリダイゼーション（ISH）
・マイクロアレイ
・マススペクトロメトリー
・その他技術
※(市場規模US$)
◆がんタイプ別、市場-2024年
・乳がん
・肺がん
・結腸直腸がん
・前立腺がん
・メラノーマ
・その他がんタイプ
※(市場規模US$)
◆バイオマーカータイプ別、市場-2024年
・遺伝子バイオマーカー
・タンパク質バイオマーカー
・その他バイオマーカー
※(市場規模US$)
◆用途別、市場-2024年
研究
・バイオマーカー探索
・パーソナル医療
臨床
・診断
・予後診断
・モニタリング、治療
・スクリーニング
※(市場規模US$)
◆主要国地域別市場-2024年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス分析（ドライバー、障壁、機会、課題）
・競合状況
◆がんプロファイリングの主要企業プロフィール動向
・ILLUMINA, INC.
・QIAGEN N.V.
・NEOGENOMIC LABORATORIES, INC.
・シスメックス株式会社
・HTG MOLECULAR DIAGNOSTICS, INC.
・HELOMICS CORPORATION
・GENOMIC HEALTH, INC.
・CARIS LIFE SCIENCES
・NANOSTRING TECHNOLOGIES, INC.
・RIBOMED BIOTECHNOLOGIES, INC.
・GUARDANT HEALTH, INC.
・FOUNDATION MEDICINE
（全224頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
英文詳細目次(table of contents)
【原文詳細目次】
Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
Table of Contents
1.... Introduction
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1.1 MARKETS COVERED
1.3.1.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS
2.... RESEARCH METHODOLOGY. 22
2.1 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY RESEARCH
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.1.2.2 BREAKDOWN OF PRIMARIES
2.1.2.3 KEY INDUSTRY INSIGHTS
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION APPROACH
2.4 ASSUMPTIONS FOR THE STUDY
3.... EXECUTIVE SUMMARY
4.... PREMIUM INSIGHTS
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2019–2024)
4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2019 VS. 2024)
5.... MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 INCREASING INCIDENCE OF CANCER
5.2.1.2 INCREASING USE OF BIOMARKERS IN CANCER PROFILING
5.2.1.3 INCREASING CANCER RESEARCH AND FUNDING
5.2.1.4 TECHNOLOGICAL ADVANCEMENTS
5.2.2 MARKET RESTRAINTS
5.2.2.1 HIGH CAPITAL INVESTMENT
5.2.2.2 TECHNICAL ISSUES WITH SAMPLE COLLECTION AND STORAGE
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE
5.2.3.2 GROWING NEED FOR POINT-OF-CARE DIAGNOSTICS
5.2.4 MARKET CHALLENGES
5.2.4.1 LOW BIOMARKER DISCOVERY-TO-APPROVAL RATIO
5.2.4.2 POOR REGULATORY AND REIMBURSEMENT SCENARIO
6.... INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 INTEGRATION OF OMICS DATA
6.2.2 ADVANCES IN LIQUID BIOPSY
6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE
7.... CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
7.3 NEXT-GENERATION SEQUENCING
7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
7.4 POLYMERASE CHAIN REACTION
7.4.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
7.5 IN SITU HYBRIDIZATION
7.5.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
7.6 MICROARRAYS
7.6.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
7.7 MASS SPECTROMETRY
7.7.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS. 62
7.8 OTHER TECHNOLOGIES. 63
8.... CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE
8.1 INTRODUCTION
8.2 BREAST CANCER
8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
8.3 LUNG CANCER
8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS HAS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
8.4 COLORECTAL CANCER
8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
8.5 PROSTATE CANCER
8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
8.6 MELANOMA
8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
8.7 OTHER CANCERS
9.... CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE
9.1 INTRODUCTION
9.2 GENETIC BIOMARKERS. 79
9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
9.3 PROTEIN BIOMARKERS. 80
9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
9.4 OTHER BIOMARKERS
10.. CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 RESEARCH APPLICATIONS
10.2.1 BIOMARKER DISCOVERY
10.2.1.1 BIOMARKERS ARE BEING EXPLOITED FOR THE DEVELOPMENT OF PERSONALIZED OR PRECISION MEDICINE
10.2.2 PERSONALIZED MEDICINE
10.2.2.1 THE FIELD OF PERSONALIZED MEDICINE IS WITNESSING RAPID GROWTH IN THE AREA OF ONCOLOGY
10.3 CLINICAL APPLICATIONS
10.3.1 DIAGNOSTICS
10.3.1.1 TUMOR PROFILING IS RAPIDLY GAINING MOMENTUM IN THE AREA OF DIAGNOSTICS
10.3.2 PROGNOSTICS
10.3.2.1 ADVANCEMENTS IN MOLECULAR BIOLOGY ARE AIDING THE UPTAKE OF TUMOR PROFILING IN THIS SEGMENT
10.3.3 MONITORING & TREATMENT
10.3.3.1 MULTIPLATFORM PROFILING ANALYSES ARE GAINING RECOGNITION FOR MONITORING AND TREATMENT AMONG CANCER PATIENTS
10.3.4 SCREENING
10.3.4.1 SCREENING TESTS HELP IN DECIDING IF DIAGNOSTIC TESTS ARE REQUIRED BY THE PATIENT
11.. CANCER/TUMOR PROFILING MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 US DOMINATES THE NORTH AMERICAN CANCER/TUMOR PROFILING MARKET
11.2.2 CANADA
11.2.2.1 GROWING PUBLIC-PRIVATE PARTNERSHIPS TO PROMOTE PROTEOMICS RESEARCH ARE EXPECTED TO DRIVE THE MARKET IN CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 ADVANCEMENTS PROTEOMICS AND GENOMICS RESEARCH ARE EXPECTED TO DRIVE MARKET GROWTH
11.3.2 UK
11.3.2.1 GROWTH IN THE LIFE SCIENCE INDUSTRY AND THE INCREASE IN ACADEMIA-INDUSTRY PARTNERSHIPS WILL BE THE KEY FACTORS DRIVING THE MARKET
11.3.3 FRANCE
11.3.3.1 GROWTH IN THIS MARKET IS PRIMARILY DRIVEN BY INCREASING INVESTMENTS IN LIFE SCIENCE R&D FOR INFRASTRUCTURAL DEVELOPMENT
11.3.4 ITALY
11.3.4.1 INCREASING INVESTMENT IN CANCER AND TRANSLATIONAL RESEARCH IS EXPECTED TO PROPEL MARKET GROWTH DURING THE FORECAST PERIOD
11.3.5 SPAIN
11.3.5.1 RISING INCIDENCE OF CANCER AND INCREASING FOCUS ON CANCER BIOMARKERS BY VARIOUS MEDICAL SOCIETIES TO SUPPORT MARKET GROWTH IN SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.1.1 LARGE NUMBER OF RESEARCH INITIATIVES TOWARDS THE DEVELOPMENT OF PRECISION MEDICINE SUPPORTING MARKET GROWTH IN JAPAN
11.4.2 CHINA
11.4.2.1 CHINA HAS THE FASTEST-GROWING RESEARCH SECTOR IN THE APAC REGION
11.4.3 INDIA
11.4.3.1 INCREASING PHARMA R&D AND GOVERNMENT FUNDING IN THE BIOTECHNOLOGY INDUSTRY ARE THE MAJOR FACTORS DRIVING MARKET GROWTH IN INDIA
11.4.4 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH.. 148
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH
12.. COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE LEADERSHIP MAPPING
12.2.1 VISIONARY LEADERS
12.2.2 INNOVATORS
12.2.3 DYNAMIC DIFFERENTIATORS
12.2.4 EMERGING COMPANIES
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS. 158
12.3.2 EXPANSIONS
12.3.3 ACQUISITIONS
12.3.4 OTHER STRATEGIES
13.. COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
13.1 ILLUMINA, INC.
13.2 QIAGEN N.V.
13.3 NEOGENOMIC LABORATORIES, INC.
13.4 SYSMEX CORPORATION. 181
13.5 HTG MOLECULAR DIAGNOSTICS, INC.
13.6 HELOMICS CORPORATION. 191
13.7 GENOMIC HEALTH, INC. 195
13.8 CARIS LIFE SCIENCES. 198
13.9 NANOSTRING TECHNOLOGIES, INC.
13.10 RIBOMED BIOTECHNOLOGIES, INC.
13.11 GUARDANT HEALTH, INC.
13.12 FOUNDATION MEDICINE. 209
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14.. APPENDIX
LIST OF TABLES
TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS 42
TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS
TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS
TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS
TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 6 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 7 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 20 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 25 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 26 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 29 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 39 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 40 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 41 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 42 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 43 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 44 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 45 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 46 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 47 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 48 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 49 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 51 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 52 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 53 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 54 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 55 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 57 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 58 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 59 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 61 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 62 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 63 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 64 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 65 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 66 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 67 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 68 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 69 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 71 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 72 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 73 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 74 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 76 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 77 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 78 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 79 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 ROE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 82 ROE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 83 ROE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 84 ROE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 ROE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 87 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 88 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 90 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 91 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 92 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 93 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 94 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 95 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 96 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 97 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 98 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 99 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 100 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 101 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 103 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 104 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 105 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 106 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 107 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 108 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 109 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 110 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 111 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 112 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 113 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 114 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 115 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 119 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 120 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
LIST OF FIGURES
FIGURE 1 CANCER/TUMOR PROFILING MARKET 20
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY 28
FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION)
FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2019 VS. 2024 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET
FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH IN THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 36
FIGURE 14 APAC TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST
PERIOD (2019–2024)
FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2019 & 2024
FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 GLOBAL CANCER INCIDENCE, 2008–2030
FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016
FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
FIGURE 20 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 21 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 22 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
FIGURE 23 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
FIGURE 24 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 25 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 26 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2018)
FIGURE 27 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 28 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 30 ILLUMINA, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT (2018)
FIGURE 32 NEOGENOMIC LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 33 SYSMEX CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 34 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 35 GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 36 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 37 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 38 FOUNDATION MEDICINE: COMPANY SNAPSHOT (2018)
掲載企業リスト
プレスリリース
プレスリリース
当レポートのプレスリリースは発行されておりません。
リサーチカテゴリ一覧
スマートグリッド
お問合わせはこちらから
